Biozoom, Inc.

CIK:0001438576|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		73 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
REVENUE
Sales-Net			$ 1,500
Total Revenue			1,500
EXPENSES
Cost of sales			1,500
Rent	6,382		19,382
Consulting Fees			9,234
Professional Fees	81,721		291,971
Research and Development	45,000	4,800	145,000
Other Selling, General and Administrative	195,568	1,965	263,746
Total Expenses	328,671	6,765	730,833
Net Loss from Operations	(328,671)	(6,765)	(729,333)
Other Income (Expense)
Extinguishment of Debt			120,782
Interest Expense		(1,361)	(13,967)
Total Other Income (Expense)		(1,361)	112,908
Net Income (Loss)	$ (328,671)	$ (8,126)	$ (616,425)
PER SHARE DATA:
Basic and diluted loss per common share
Weighted Average Common Shares outstanding	59,800,604	59,730,000

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended		73 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
CASH FLOW FROM OPERATING ACTIVITIES:
Net income (loss)	$ (328,671)	$ (8,126)	$ (616,425)
Adjustments to reconcile net income (loss) to net Cash provided by operating activities:
Depreciation	1,124		1,495
Amortization of intangibles	2,616		3,507
Issuance of common stock for services	40,000		40,000
Issuance of common stock for employee compensation	78,000		78,000
Debt extinguishment			(120,782)
Changes in operating assets and liabilities
Prepaid Expenses	(155,011)		(187,511)
Accrued liabilities - related parties		81	(117,657)
Accrued liabilities	1,710	41	135,981
NET CASH USED IN OPERATING ACTIVITIES	(360,232)	(8,004)	(783,392)
CASH FLOW FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(2,354)		(2,354)
Purchase of intangible assets	(21,398)		(21,398)
Purchase of investments	(9,950)		(9,950)
NET CASH USED IN INVESTING ACTIVITIES	(33,702)		(33,702)
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from loans payable - related parties			6,500
Proceeds from issuance of preferred stock			1,150,000
Proceeds from issuance of notes payable		6,000	74,400
Debt issued for research and development			100,000
Proceeds from sale of common stock			66,100
NET CASH PROVIDED BY FINANCING ACTIVITIES		6,000	1,397,000
NET INCREASE (DECREASE) IN CASH	(393,934)	(2,004)	579,906
CASH, BEGINNING OF PERIOD	973,840	2,944
CASH, END OF PERIOD	579,906	940	579,906
Noncash investing and financing activities:
Cancellation of common shares			39,000
Purchase of property with debt			50,000
Purchase of intangibles for common stock			$ 205,196

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2013	Mar. 31, 2013
CURRENT ASSETS
Cash	$ 579,906	$ 973,840
Prepaid Expenses	187,511	32,500
Total Current Assets	767,417	1,006,340
NON-CURRENT ASSETS
Investments	38,087	28,137
Property and Equipment, net	22,722	21,492
Intangibles, net	223,087	204,305
Total Non-Current Assets	283,896	253,934
TOTAL ASSETS	1,051,313	1,260,274
CURRENT LIABILITIES
Accrued Liabilities	125,942	124,232
Note Payable	2,500	2,500
Total Current Liabilities	128,442	126,732
TOTAL LIABILITIES	128,442	126,732
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred Stock, $.001 par value 10,000,000 shares authorized, 1,150,000 issued and outstanding as of June 30, 2013 and March 31, 2013	1,150	1,150
Common Stock, $.001 par value 100,000,000 shares authorized, 60,025,000 and 59,730,000 shares issued and outstanding as of June 30, 2013 and March 31, 2013, respectively	60,025	59,730
Additional paid-in capital	1,478,121	1,360,416
Deficit accumulated during the development stage	(616,425)	(287,754)
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	922,871	1,133,542
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 1,051,313	$ 1,260,274